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Prophylaxis of Opportunistic 
Infections May Be Our Most Important 
Intervention - An Update 
Until antiviral regimens improve, 
prophylaxis against pneumocystis and 
other opportunistic infections remains our 
most effective intervention in HIV 
disease. Use of trimethoprim-sulfa for 
pneumocystis prevention has clearly 
prolonged survival of AIDS patients. 
However, as pneumocystis pneumonia 
has decreased in incidence, other 
opportunistic infections have become 
more troublesome. Therefore, the role of 
prophylaxis against disseminated 
mycobacterium avium complex (MAC), 
toxoplasmosis, CMV disease, and fungal 
infections is receiving careful scrutiny. 
For patients with CD4 Counts 
<200, trimethoprim sulfa is the drug of 
choice for primary prophylaxis against 
pneumocystis pneumonia. It is the most 
effective choice, least costly, and has the 
additional benefit of preventing toxo-
plasmosis encephalitis. The majority of 
patients with an initial drug rash or fever 
from trimethoprim-sulfa may be 
successfully rechallenged, or desensitized. 
Alternatives such as dapsone and aerosol 
pentamidine are less effective than 
trimethoprim-sulfa, and pentamidine is 
more costly. 
Rifabutin has been approved for 
prevention of disseminated MAC in 
patients with CD4 counts <100: Most 
clinicians believe that MAC prophylaxis is 
best begun at CD4 Counts of 50 or less. 
Several recent studies now document the 
effectiveness of clarithromycin for MAC 
prophylaxis. Some clinicians recommend 
routine blood cultures for MAC to rule 
out dissemination before starting 
prophylaxis. Both rifabutin and 
clarithromycin appear to lower the 
incidence of bacteremia due to MAC by 
50%. No impact on overall survival has 
yet been demonstrated, but a recent 
"quality of life" analysis supports 
prophylaxis for MAC. 
For seropositive patients, 
toxoplasmosis encephalitis can be 
prevented with either trimethoprim-sulfa 
or dapsone combined with 
pyrimethamine. Prophylaxis is usually 
recommended at CD4 counts <200. 
The possible role of fluconazole 
for prophylaxis of cryptococcal meningitis 
is controversial. This infection is less 
common than other OI's mentioned 
above, and therefore the role of 
prophylaxis is less clear. 
Finally, with the release of oral 
gancyclovir, prevention of CMV retinitis 
(and other disseminated CMV disease) 
may be possible in the near future . 
Preliminary results suggest an 
effectiveness of 50% with oral gancyclovir 
prophylaxis of CMV retinitis. However 
oral gancyclovir is not yet approved for 
primary prophylaxis. 
Current recommendations for 
prophylaxis of opportunistic infections are 
summarized in the enclosed insert. 
FDA Approves Oral 
Gancyclovir 
As of January 1995, the FDA 
has approved the use of oral gancyclovir 
for maintenance therapy of CM\! retinitis. 
In several pilot studies, oral gancyclovir 
(lgm po tid) appeared equally effective 
with IV regimens for the prevention of 
relapse of CMV retinitis once the 
infection has been controlled. Side 
effects (granulocytopenia, nausea) are 
less frequent than with the IV forms. 
Although preliminary information 
suggests oral gancyclovir may be effective 
for primary prophylaxis of CMV retinitis, 
the drug has not yet received FDA 
approval for this indication . 
Recommendations regarding its possible 
use will depend on the final results of 
several studies now in progress. 
Another new development in 
the treatment of CMV retinitis is the use 
of intraocular implants of a plastic 
membrane that releases gancyclovir. 
Initial studies are promising. A research 
trial at New England Eye Center 
(617)636-4604) is currently evaluating 




Recognition of Clinical Syndromes 
Associated with Opportunistic Infections 
Although the manifestations of many opportunistic infections in persons with HIV are variable, there are specific clinical 
syndromes that are often caused by particular opportunistic infections. With continued improvement in treatment, it is often possible 
to suppress these infections with an associated improvement in the person's well being. In general, the level of the CD4 cell count is 
a key predictor of the likelihood of some of these infections. Most of the serious opportunistic infections are rarely seen when CD4 
counts are greater than 100. Some common clinical scenarios are outlined below according to these CD4 count benchmarks. 
CD4 Count <200 
Chronic Cough 
Persistence of a dry cough for 
greater than 2 weeks in a person with a 
CD4 count <200 should raise the 
suspicion of pneumocystis pneumonia. 
Although viral respiratory infections are a 
more common cause, persistence of 
cough, particularly if accompanied by a 
sense of breathlessness, is the typical 
presentation of pneumocystis pneumonia. 
Although trimethoprim sulfa prophylaxis is 
very effective, PCP still occurs, and is a 
particular concern in patients on less 
effective prophylactic regimens. Other 
considerations include tuberculosis, viral 
and bacterial pneumonias. 
Chest x-rays may detect mixed 
alveolar interstitial infiltrates characteristic 
of PCP, but may be negative early in the 
disease. Diagnosis of PCP usually 
requires detection of organisms by 
immuno-fluorescence or silver stain of 
individual sputum or bronchoscopic 
washings. Less severe cases of PCP may 
be treated as outpatients on oral regimens 
as noted on the insert page. 
CNS Symptoms 
Many patients with low CD4 
counts experience mild memory 
disturbance, sometimes coupled with mild 
ataxia or motor impairments. In most 
cases, these symptoms are due to HIV 
encephalopathy. However, CNS 
opportunistic infections such as 
cryptococcol meningitis, CNS 
toxoplasmosis , or neurosyphilis are other 
considerations. Cryptococcal meningitis is 
often indolent with headaches and gradual 
mental status decline. CNS toxoplasmosis 
often causes focal neurologic symptoms or 
seizures, but may present without non-
specific CNS changes. Neurosyphilis, 
which can occur within a few years of 
treated primary syphilis in HIV+ patients, 
can cause of variety of CNS symptoms. 
Rarely, patients may develop progressive 
multifocal leukoencephalopathy which, as 
it's name suggests, typically presents with 
a history of focal neurologic deficits that 
occur in a stuttering course. 
The usual diagnostic approach 
requires CT or MRI scans of the brain (the 
latter is more sensitive for the detection of 
the mass lesions of toxoplasmosis) . CNS 
toxoplasmosis is unlikely in patients who 
are seronegative for toxoplasma 
antibodies . However, if mass lesions are 
detected, an empiric trial of treatment for 
toxoplasmosis encephalitis is often 
attempted. Toxoplasmosis usually 
responds clinically within 2 weeks. If no 
response is evident, brain biopsy is usually 
done to obtain a specific diagnosis . 
Diffuse white matter involvement with 
cortical atrophy is usually indicative of 
HIV encephalopathy, while multifocal 
white matter lesions may suggest 
progressive multifocal leuko-
encephalopathy. 
If imaging studies are negative, a 
lumbar puncture is indicated to rule out 
cryptococcal meningitis (with cryptococcal 
antigen and culture), neurosyphilis (CSF 
VDRL), and other inflammatory CNS 
processes. 
Effective treatment may suppress 
CNS toxoplasmosis , cryptococcus , or 
syphilis. Some patients with HIV 
encephalopathy may have transient 
improvement with a change or increase in 
antiretroviral regimens. However, no 
effective treatment exists for HIV 
encephalopathy or progressive multifocal 
leukoencephalopathy. 
CD4 Count <l 00 
Feuer and Wasting Syndrome 
Recurrent fever, night sweats, 
and weight loss may be due to endstage 
HIV disease alone, but may also signify 
opportunistic infections such as 
disseminated mycobacterial infection or 
lymphoma. 
Disseminated mycobacterium 
infection has an incidence of 30% in 
patients with CD4 count <50, and often 
presents with nonspecific systemic 
symptoms as noted above, sometimes 
accompanied by diarrhea and anemia. 
Mycobacterium avium organisms are 
ubiquitous in the environment, and have 
been shown to be occasionally acquired 
from hospital tapwater as well . Diagnosis 
is usually made by blood culture {specified 
for mycobacteria), or less frequently be 
culture of other sites or biopsies (bone 
marrow, lymph node, colon, etc.). Once 
diagnosed, symptoms of disseminated 
MAC can often be suppressed with 
antibiotic regimens (see insert) . 
Chronic Diarrhea 
Chronic diarrhea may represent 
HIV enteropathy, but may also be due to 
enteric bacterial pathogens (ie. salmonella, 
campylobacter, etc.) or disseminated 
mycobacterial avium infection involving 
the colon. Cryptosporidium, a water-
borne parasite, can cause voluminous 
watery diarrhea, as can other similar 
parasites such as microsporida. CMV 
infection of the colon may also cause 
diarrhea, often associated with painful 
abdominal cramping. The workup of 
persistent diarrhea includes stool 
examinations for enteric bacteria, and ova 
and parasite exams. The latter should 
include special procedures for the 
detection of cryptosporidia. As many of 
these patients are on chronic antibiotic 
therapy for Ol prophylaxis, a stool for c. 
difficile toxin is often appropriate as well. 
Blood cultures for MAC are usually 
indicated. 















;tdmln. Treatment ;R.eglmen Comments 
'PO \ Trlmetltoprlm-Sulfa (15-mg/kg/d . 'Preferred treatment regimen I trlmetltoprlm - give as divided dose qld) ~ 
'PO j Trlmetltoprlm(J5 mg/kg/d) · j .Alternative for sulfa-allergic 
1 Dapsone (JOOmg po qd) 1 patient Check G6ID status. 
······························1·············· .. ················································································ ·· ······1······················································································ 
'PO \ ;Itovoquone (750 mg po tld) \ Costlv. Bloavallabllltv resists 
l \ proper distribution. 
: : 
IV \ Trlmethoprlm-sulfa l Same dose as po reqlmen 
l 1 
IV l Pentamtdtne (4mq/ kq/d/lv or Im) ! 
l ........................... · ... · · · ········ ···· ··········1······················································································ 
IV l Trtmetrexate l See packaqe Insert for dose 
l ) recomm. 
IV ! C/tndamvctn (600mq IV q 6hr or 300mq ! . 
l po qtd) & prlmaqulne (J5mq base po/dav 1 
IV 
l x2 davs) l 
I ;.;;:;;;;;;;;;;;;;~; :;;: T:i::~:;i;i::;::i:~:::: 
l ! treatment. 
C/arlthromvctn (500·1000 mq po btd) · 
Usual/If In comb-lnatlon with ethambutol 
(J5mq/kq/d) with or without rlfabutln. 
(Other aqents to consider Include 
clofazlmlne. clprofloxacln. amlkac/n) 
Indefinite duration 
Gancvclovlr (5mq/ kq IV bid) or foscarnet 2 week Induction reqlmens 
1 (60mq/lv q8hs or 90mq/kq/IV q12 hrs) . 
IV/ PO I Maintenance with qancvclovlr I MaJor toxicities of Gancvclovlr: 
IV 
i (5mq/kq/lv/qd) or foscarnet(90- i 
I ;:::~~:::) o,af ;Jgram po ttd) I 
Amphoterlcln B (0.4·0.8 mq/kq/d) · 
/ J]ucvtoslne (J00-150 mq/kq/d divided qtd) j 
Bone Marrow Suppression 






t,.j J]uconazole (400 mq/d) i,_i Maintenance with fluconazole 
usuallv prdered 
'Pi;rlmethamlne (J00·200mq /oadlnq dose. 
then 50-100 mq/d po x6 wks) and fol!c 
acid (lOmq/d/po) plus Su/fadla2!ne (4.8 
q/d po x6 wks) 
No treatments of proven dfectlveness 
Acute manaqement. Chronic 
suppression Is also required at 
modified doses. 
Of possible benefit: 
Paromomvctn 
· 11e lntormatlon contained In this Insert Is current as of .,March 1995. 




1) anv patient with a past 
htstorv of pneumocvstls 
2) more than 2 weeks wasting 





C.MV · disseminated 
(CD4 <50) 
Crvptococcal meningitis 
I ;R_eglmens I Comments 
Trlmethoprlm·sulfa 
( one DS/d or one OS 3x/wk) 
. . 
Most effective (>95%) and least 
costlv regimen. ;R_echallenge 
often successful If drug has been 
stopped for skin rash. 
~······· ............................. ······· ....................................................... · i · ................................................................................... . 
l Dapsone (50·100 mg/dav) l less effective. 30% reaction In 
\ pvrlmethamlne ( 25·50mg/d) l sulfa Intolerant patients. 
~-··· ..... ·······.... ......... ....... ...... .. . ........... ... .......... ............ . . . . l . . . . ............................................................. . 
j ;lerosol pentamldlne (300mg/month} j Cess effective. costlv. 
. . 
[ Jc.lfabutln (300mg/dav) [ 50% effective. Watch drug 
l l Interactions with fluconazole 
I Ci~;;;;;;;,;;;; ;;;;;;·;;,;;,;;; ···············!··· :::/,e;;:;,:~;;;i;; ;;~b:;;;: 
Trlmethoprlm-sulfa ( one OS / dav) 
.. ;~;~~~;:;~;;;;h~~;~; .. ;~~ .. ~b~;;;""""'"I"""""""""'""""""""'""'"""""'""""""""""""""""""""" 
None vet approved ;lcvclovlr · Ineffective 
r····· ............................................................................................. , ···; .. ·o;~;·c~~·;;;~~;~ .. ;~~; .. ~;; ........... . 
approved for prlmarv 
prophvlaxls) 
??? .fluconazole 
(Not approved for prophvlaxls) 
Cost-effectiveness Is unclear. 
Mav Increase fluconazole 
resistance. 
lte Information contained In tltls Insert Is current as ot .A{arclt 1995 
Medication Costs for OJ Prophvlaxls 
I I 
Drug Name Trade Name : Dosage : "Price Per Month *;;lccess Information 
I I I I 
;lcvclovlr : Z.ovlrax : 800mg qd : $156.00 · 198.00 : P )l 1·800·7 22·9294 
-----------------T-------------------;---------------------r----------------------------T-----------------------
T,iU'P-S,iUc. ! Bactrlm OS ! 1 tab 3x/week ! $6.20 · 9 .80 ! 
-----------------r--------------------+-------------------+----------------------------r-----------------------
Clarlthromvcln ! Blaxln ! SOOmg bid ! $173.00 · 206.00 ! Info 1·800·688·9118 
-----------------r--------------------+-------------------+----------------------------r-----------------------
I I I I 
Dapsone : Dapsone : 100mg qd : $630 · 9.80 : 
-----------------r--------------------+-------------------+----------------------------r-----------------------
;R_1fabutln ! Mvcobutln ! 150mg bid ! $210.00 · 228.00 ! P )l 1·800·795-9759 
-----------------r--------------------+-------------------+----------------------------r-----------------------
.fluconazole ! Dltlucan ! 100mg qd ! $204.00 · 224.00 ! P )l 1·800-869·9979 
Yrlce Information (lat/\ered from niarmacles (7) In 'f'ort/and. ~. rort/and. ~cartJorou(llt. & Grav. 
•p ;;t = Patient ;;lsslstance "Programs 
Continued from page 2 
If these measures are unrevealing, lower 
and upper GI endoscopy with biopsy may 
be necessary for a definite diagnosis . 
Treatable diseases that can be diagnosed 
only by biopsy include CMV colitis and 
MAC infection of the GI tract. 
Visual Disturbance 
CMV retinitis is a sight threatening 
infection that can be suppressed with 
antiviral therapy. It often presents with 
localized visual blurring. Fundoscopic 
exam may reveal characteristic white 
exudates with hemorrhage in a perivascular 
distribution. As lesions often begin in the 
periphery of the retina, slit lamp 
examination with pupil dilation may be 
necessary to make the diagnosis . Although 
toxoplasmosis may also cause a retinitis, it 
is usually associated with vitreitis as well. 
Herpes zoster can cause a necrotizing 
retinitis that is poorly responsive to antiviral 
therapy. Other infections that may rarely 
affect the eyes of patients with HIV include 
pneumocystis choroiditis, fungal and 
bacterial endophthalmitis, and optic neuritis 
due to syphilis . 
Disseminated Skin Lesions 
New onset of papular or 
indurative skin lesions may follow 
dissemination of bacteria (mycobacterium 
avium), fungi (cryptococcus, 
histoplasmosis), and virus (CMV) . 
Exposure to cats may lead to bacillary 
angiomatous, a variant of cat scratch 
disease seen in AIDS patients, that is 
characterized by multiple erythematous 
papules or angiomas. At times, bacillary 
angiomatous can be confused with Kaposi's 
sarcoma. The distinction between these 
two conditions is critical, as bacillary 
infections can be cured with antibiotic 
treatment. More commonly, papular 
eruptions are due to xerosis, eosinophilic 
folliculitis, or other AIDS-related skin 
ailments. Skin biopsy often reveals the 
diagnosis of disease in these patients, and 
silver staining should be requested when 
bacillary angiomatosis is a consideration. 
Maine Bureau of Health Issues Guidelines for 
Prevention of Cryptosporridiosis Infection 
Cryptosporidiosis in normal hosts is a self limited enteric illness caused by a 
protozoan parasite. It is usually transmitted by ingestion of contaminated water. In 
persons with HIV disease, cryptosporidiosis can become a life threatening infection for 
which no standard therapy exists. Since the 1993 outbreak of cryptosporidiosis in the 
Milwaukee water supply, attention has been focused on the safety of public water 
supplies with regard to cryptosporidiosis and other enteric parasites. Although no 
standard method for assessing risk in local water supplies has yet been agreed upon, a 
national survey of public water systems is planned. At the present time, there is no 
evidence that public water supplies pose a significant risk of cryptosporridia exposure 
in Maine. However, the Maine Bureau of Health has issued the following suggestions 
for prevention of exposure to this parasite: 
• do not drink water directly form rivers or lakes or other surface water 
sources 
• swimming in freshwater or even chlorinated pools (the organism is resistant to 
chlorine), is a possible risk 
• in the event of a local outbreak of infection, boiling water for 1 minute will 
eliminate risk 
• avoid unpasteurized milk or other unpasteurized dairy products 
AIDS Consultation Service to Participate in 
Trial of Experimental Protease Inhibitor 
Protease inhibitors show promise as antiretroviral agents, with much higher 
in vitro potency against HIV than currently available medications. In collaboration 
with the Community Research Initiative of Boston, the ACS will participate in a trial 
of a protease inhibitor developed by Abbott Laboratories (ABT-538) . The initial trial 
will be open for patients who have not previously received AZT, and will compare 
AZT plus ABT-538 with AZT plus placebo. A second trial will offer ABT-538 or 
placebo to patients with CD4 counts <100, provided they have previously been on 
antiretroviral treatment for 9 months . We hope this will be the first of several clinical 
trials of this regimen in Maine. Inquiries regarding this study can be made to the 
AIDS Consultation Service at 1-800-871-2701. 
Other on-going clinical trials at AIDS Consultation Service include the 
experimental non-nucleoside RT-inhibitor, Delavirdine, with either AZT, DD!, or a 
triple combination regimen. 
AIDS Consultation Service Offers 
Information FAX Service 
The AIDS Consultation Service at Maine Medical Center 
has initiated an information fax service to distribute bulletins on 
HIV care, updated CDC recommendation, and other information 
useful in the care of persons with HIV. If you would like to 
receive this information free of charge, contact Kathy Anderson 
at the AIDS Consultation Service at (207)871-2099 or fax your 
name, address, and fax number to (207)871·6116. If you do not 
have a fax machine and wish to obtain this information through 
the mail, please forward your name and address to Kathy 
Anderson, AIDS Consultation Service, 22 Bramhall Street, 
Portland Maine 04102-3175. 
World ;VDS Cases 2.soo.oocr 
US ;UDS Cases 4343971 
US ;UDS Deaths 220.8712 
:Maine ;VDS Cases 592 
:Maine ;UDS Deaths 291 
}.(a!ne Data as of December 31. 1994 
• Esrtmated 
I J?..eported throu(lh J/6/95 bv CDC 
' Total US deaths reported throu(lh 12/31/ 93 bv CDC 
Upcominq ]{IV/ .;tJDS Education 
03/07/95 "HIV Update for the Emergency Room" 
Winter Emergency Medicine Symposium at Sunday River Bethel Maine 
Robert P. Smith, M.D. 
03/28/95 "Update on Management of HIV+ Patients" 
Grand Rounds, Kennebec Valley Medical Center, Augusta, Maine 04330 






"Living with HIV: Client/Provider Perspectives" 
Eastern Nursing Research Society 7th Annual Scientific Sessions 
Sheraton Tara Hotel, So. Portland, Me. 
Sandra T. Putnam, RN,MSN,FNP 
"HIV in the Office Practice" 
Family Medicine Symposium at the Sonesta Hotel, Portland Maine 
Robert P. Smith, MD. 
"HIV Update" 
Goodall Hospital, Sanford Maine 
Sandra Putnam, RN,MSN,FNP 
"Early Treatment of the HIV Positive Patient" 
Ambulatory Care Coalition Teleconference 
"HIV/ AIDS: Moving from Fear and Discrimination to Empowerment" 
Holiday Inn By the Bay, Portland Maine 
USM's Dept of Cont. Ed. for Health Professionals (207)780-5951 
If you are providing an HIV/AIDS realted educational session. please Jet us know at (207)871-2099 
Maine Medical Center 
AIDS Consultation Service 
22 Bramhall Street 
Portland, Maine 04102-3175 
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